Lamotrigine Tablet, Film Coated, Extended Release
Product Images NDC 42291-444

Product Visual Gallery

This gallery contains 15 technical images submitted to the FDA as part of the official labeling for Lamotrigine (NDC 42291-444). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Avkare, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

25mg (443 30 25mg)

This appears to be a product label for Lamotr, a medication that comes in extended-release tablets. The label cautions that the product is available for prescription only and is intended to be taken once a day. Each bottle contains 30 tablets. The rest of the text is not legible due to errors.*

FDA Label Image

50mg (444 30 50mg)

FDA Label Image

100mg (445 30 100mg)

FDA Label Image

200mg (446 30 200mg)

This appears to be a medication label for the drug Lamotrigine, which comes in the form of 200 mg extended-release tablets. It is intended to be taken once a day and caution is advised when dispensing the product. The label also includes a National Drug Code (NDC) and a phone number to contact the manufacturer (KARE.).*

FDA Label Image

250mg (447 30 250mg)

This appears to be a mixture of scrambled text and relevant information. The available text describes a tablet of "Lamotr" in a "Vority Product Dispensed" format. It is proposed for "Rx Only." The tablet is an "Extended-Release" medicine and should be taken "Once A Day." The tablet is cautioned to dispense, and the packaging consists of "30 Tablets." The rest of the text is non-readable or garbled.*

FDA Label Image

300mg (448 30 300mg)

The text appears to be a description of a medication named "Lamotrigine" which is extended-release tablets to be taken once daily, with a warning for its use. There is also a caution statement mentioned. However, there is not enough information available on its directions, usage, and side effects to provide a comprehensive description of the medication's benefits or drawbacks.*

FDA Label Image

Structural Formula (Lamotrigine Extended Release Tablets Usp 1)

FDA Label Image

Figure 1 (Lamotrigine Extended Release Tablets Usp 2)

This appears to be a chart or graph displaying the responder rates and improvement/worsening percentages for Lamotrigine Extended-Release and Placebo treatments, with numbers and percentages shown for each group. The text does not provide any further context or explanation.*

FDA Label Image

Figure 2 (Lamotrigine Extended Release Tablets Usp 3)

FDA Label Image

Q (Lamotrigine Extended Release Tablets Usp 4)

FDA Label Image

W (Lamotrigine Extended Release Tablets Usp 5)

FDA Label Image

R (Lamotrigine Extended Release Tablets Usp 6)

FDA Label Image

Y (Lamotrigine Extended Release Tablets Usp 7)

FDA Label Image

N (Lamotrigine Extended Release Tablets Usp 8)

FDA Label Image

B (Lamotrigine Extended Release Tablets Usp 9)

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.